Celgene Corporation., CELG - Celgene slips as analyst doubts Revlimid sales
Shares of Celgene Corp. gave up some of their recent gains after an analyst downgraded the stock, saying the biotechnology company and its cancer drug Revlimid may not meet Wall Street's expectations.